Skip to main content

DC/AML Fusion Vaccine

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

  • RegistryNCT07374029
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAcute Myeloid Leukemia
  • SponsorDavid Avigan
How DC/AML Fusion Vaccine worksNCT073740291 min

What the film says

Read the transcript

This trial is for acute myeloid leukemia, in patients treated with decitabine and venetoclax.

The idea: add personalized immune cells. A vaccine is made by fusing a patient's dendritic cells with their own leukemia cells. T cells stimulated by that fusion are collected, grown, and given back by vein.

This is the first time these primed T cells will be given to people. The study asks about feasibility and safety. At Beth Israel Deaconess in Boston, David Avigan leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07374029

    AML newly diagnosed or relapsed, treated with decitabine and venetoclax; Vaccine of patient's dendritic cells fused with their own leukemia cells; T cells stimulated by the fusion collected, grown and given back by vein; First time these primed T cells will be given to people (+2 more lines)

The drug

What is being tested.

Autologous fusion vaccine of dendritic cells and AML cells, via subcutaneous injection (under the skin) per standard of care.

Autologous adoptive T cells, via intravenous (into the vein) infusion, per protocol.

The study is a dose escalation phase I clinical trial to evaluate the feasibility, safety, clinical and immune effects of adoptive T cell therapy with DC/AML Primed T cells in participants with acute myeloid leukemia (AML) treated with decitabine and venetoclax. The U.S. Food and Drug Administration (FDA) has not approved DC/AML Vaxprimed T cells as a treatment for any disease. This is the first time that DC/AML Primed T cells will be given to humans. The U.S.

The study

How the trial runs.

The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and venetoclax is feasible and safe and effective for treatment of acute myeloid leukemia (AML).

The names of the study drugs involved in this study are: * DC/AML fusion vaccine (immune cell vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone) * DC/AML Primed T cells (immune cells) * Decitabine (a type of chemotherapy drug) * Venetoclax (a type of antineoplastic agent)

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patients must have AML at initial diagnosis for which decitabine/venetoclax is planned as standard of care therapy. This can include patients with IDH or FLT-3 mutations for whom the addition of targeted therapy agents directed at IDH or FLT-3 mutations to the decitabine/venetoclax regimen is preferred per the treating physician.
  • Patients with AML in first relapse after cytotoxic and/or targeted therapy for which decitabine and venetoclax therapy is appropriate standard of care. This can include patients with IDH or FLT-3 mutations for whom the addition of targeted therapy agents directed at IDH or FLT-3 mutations to the decitabine/venetoclax regimen is preferred per the treating physician.
  • ECOG performance status ≤ 2 (Appendix A)
  • Participants must have normal organ and marrow function as defined below:
  • total bilirubin≤ 2.0 mg/dL

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.